Extract

Funding sources: this study was supported in part by the National Institutes of Health grant U01 CA176726.

Conflicts of interest: C.K.C. is an employee of Eli Lilly and Company. J.F.M. is a consultant and/or investigator for Merck Research Laboratories, AbbVie, Dermavant, Eli Lilly and Company, Novartis, Janssen, UCB, Samumed, Celgene, Sanofi Regeneron, GSK Almirall, Sun Pharma, Biogen, Pfizer, Incyte, Aclaris and LEO Pharma.

Dear Editor, Psoriasis is a chronic immune‐mediated disease of the skin that affects approximately 2% of the US and Europe population.1 The disease presents a significant burden for affected individuals and negatively affects their quality of life. Environmental and lifestyle factors play important roles in this disease, and several complex disorders have also been linked to psoriasis.1,2 Phototherapy, performed under medical supervision, is an effective treatment for psoriasis.1 Indoor tanning produces artificial ultraviolet (UV) radiation and has been shown to increase the risk of skin cancer and accelerate skin ageing.3 However, epidemiological evidence on indoor tanning usage and psoriasis has been sparse. In fact, it has sometimes been recommended that patients with psoriasis use tanning beds to control exacerbation of symptoms when office‐based UV treatment is not available.4 Here we evaluated the association between frequency of indoor tanning over a lifetime and having a diagnosis of psoriasis, using data from the Nurses’ Health Study II (NHS II), a large well‐characterized cohort of US women.

You do not currently have access to this article.